Clinical response to a lapatinib-based therapy for a Li-Fraumeni Syndrome patient with a novel HER2V659E mutation

  • Serra V
  • Vivancos A
  • Puente X
 et al. 
  • 28


    Mendeley users who have this article in their library.
  • 18


    Citations of this article.


UNLABELLED: Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline TP53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-humans HER2V659E mutation showing a phenotypic convergent evolution toward HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A symptomatic and radiologic clinical response was achieved. HER2V659E sensitivity to lapatinib was confirmed in the laboratory.

SIGNIFICANCE: The precise knowledge of the genomic alterations present in tumors is critical to selecting the optimal treatment for each patient. Here, we report the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Violeta Serra

  • Ana Vivancos

  • Xose S. Puente

  • Enriqueta Felip

  • Daniel Silberschmidt

  • Ginevra Caratù

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free